Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus

Huang, Shiang Fen; Fung, Chang-Phoné; Perng, Diahn‐Warng; Wang, Fu‐Der

doi:10.1016/j.jmii.2015.08.016

Cited by 20 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Including 30 studies identified from the previous review, we identified 31 eligible studies, of which 21 with 9536 patients were included in meta-analyses. 41,[43][44][45][46][47]50,52,53,[55][56][57][58][59][60][61][63][64][65]68,69 Our search for systematic reviews for CAP identified 346 citations. We ultimately chose a systematic review published in 2015 as the target for updating.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

Wang

Colunga‐Lozano

et al. 2020

CMAJ

204

166

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

Wang

Colunga‐Lozano

et al. 2020

CMAJ

204

166

View full text Add to dashboard Cite

“…Fourteen studies assessed individuals with H1N1pdm09 virus infection, 1 study assessed individuals with H7N9 virus infection, and 4 study assessed individuals with inter-pandemic influenza virus infection. Eight studies (1956 individuals) had useable data related to patients with ARDS 9,10, [14][15][16][17][18][19] . Fourteen studies (n = 6335) reported mortality associated with adults only.…”

Section: Resultsmentioning

confidence: 99%

“…Overall mortality in the included studies. Mortality data were reported in 15 studies [8][9][10][14][15][16][17][18][19][20][23][24][25][26][27] .…”

Section: Resultsmentioning

confidence: 99%

“…Cao et al reported that a low-to-moderate dose of corticosteroids had no statistically significant association with the risk of mortality in patients with ARDS (OR 1.69, 95% CI [0.78, 3.64]), whereas a high dose was associated with greater mortality (OR 2.89, 95% CI [1.10, 7.56]) 10 . The other four studies 9,16,17,19 showed that corticosteroid use had no association with mortality ( Fig. 3).…”

Section: Mortality In Ardsmentioning

confidence: 94%

“…In four of these studies, corticosteroid use was associated with an increased risk of developing a nosocomial infection 15,17,20,21 , while the remaining two studies did not show a statistically significantly increased odds of developing infection 10,14 . Overall, the pooled results revealed that the odds of nosocomial infection were significantly higher in patients who were administered corticosteroids than in those who were not (OR 3.15, 95% CI [1.54, 6.45], p < 0.0001), but a high level of heterogeneity was observed (I² = 82%) ( Fig.…”

Section: Nosocomial Infection Six Studies Reported An Association Bementioning

confidence: 98%

See 2 more Smart Citations

Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis

Zhou

Liu

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Influenza-related severe pneumonia and acute respiratory distress syndrome (ARDS) are severe threats to human health. The objective of this study was to assess the effects of systematic corticosteroid therapy in patients with pneumonia or ARDS. The PubMed, EMBASE, Web of Science and SCOPUS databases were searched up to July, 2019. Nineteen studies including 6637 individuals were identified, and fifteen studies (6427 patients) were included in the meta-analysis of mortality. Eighteen were observational studies and one was a randomized controlled trial (RCT). The meta-analysis results showed that corticosteroid therapy was associated with significantly higher mortality (OR 1.53, 95% CI [1.16, 2.01]) and incidence of nosocomial infection (OR 3.15, 95% CI [1.54, 6.45]). Subgroup analysis showed that among patients with unadjusted estimates, the odds of mortality were higher in patients receiving corticosteroid treatment (OR 1.98, 95% CI [1.23, 3.17]), however, among patients with adjusted estimates, the result showed no statistically significant difference between corticosteroid group and control group (OR 1.31, 95% CI [0.95, 1.80]). Current data do not support the routine use of corticosteroids in patients with influenza severe pneumonia or ARDS. RCTs are needed to provide more robust evidence. MethodsStudy eligibility criteria. This systematic review included studies fulfilling the following inclusion criteria: (a) the studies were RCTs, quasi-experimental studies, or observational studies; (b) patients had confirmed influenza-related pneumonia, ARDS (PaO 2 /FiO 2 < 300 mmHg); (c) the intervention group used corticosteroids, and the comparison group did not, with no restriction set on the dose or duration of the intervention; and (d) the outcomes were mortality, nosocomial infection, length of stay or other clinical outcomes. A study was excluded if it met any of the following criteria: (a) the study was a review article, conference abstract, case report or case series, case-control study; (b) the majority of included patients were immunocompromised; (c) insufficient data were available; (d) overlapping population; (e) studies with fewer than 20 participants. There were no restrictions on influenza subtype, patient age or study setting. If only some of the individuals included in a study fit the eligibility criteria and these individuals had extractable results corresponding to the objective of this study, then the study was included.Clinical outcomes including mortality, nosocomial infection, duration of mechanical ventilation, length of stay, time to fever alleviation and clinical stability and viral shedding were evaluated. Scientific RepoRtS |(2020) 10:3044 | https://doi.

show abstract

Corticosteroids as adjunctive therapy in the treatment of influenza

Lansbury

Rodrigo

Leonardi‐Bee

et al. 2019

Cochrane Database of Systematic Reviews

188

160

View full text Add to dashboard Cite

Background Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefits or harms. This is an update of a review first published in 2016. Objectives To systematically assess the e ectiveness and potential adverse e ects of corticosteroids as adjunctive therapy in the treatment of influenza, taking into account di erences in timing and doses of corticosteroids.

show abstract

Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus

Cited by 20 publications

References 36 publications

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis

Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis

Corticosteroids as adjunctive therapy in the treatment of influenza

Contact Info

Product

Resources

About